Gina Tourassi has been appointed as director of the National Center for Computational Sciences, a division of the Computing and Computational Sciences Directorate at Oak Ridge National Laboratory.
Kathy McCarthy has been named director of the US ITER Project Office at the Department of Energy’s Oak Ridge National Laboratory, effective March 2020.
A technology developed at the ORNL and scaled up by Vertimass LLC to convert ethanol into fuels suitable for aviation, shipping and other heavy-duty applications can be price-competitive with conventional fuels
Researchers at the Department of Energy’s Oak Ridge National Laboratory have received five 2019 R&D 100 Awards, increasing the lab’s total to 221 since the award’s inception in 1963.
The U.S. Department of Energy announced funding for 12 projects with private industry to enable collaboration with DOE national laboratories on overcoming challenges in fusion energy development.
ORNL and The University of Toledo have entered into a memorandum of understanding for collaborative research.
Electro-Active Technologies, Inc., of Knoxville, Tenn., has exclusively licensed two biorefinery technologies invented and patented by the startup’s co-founders while working at the Department of Energy’s Oak Ridge National Laboratory. The technologies work as a system that converts organic waste into renewable hydrogen gas for use as a biofuel.
A team of scientists led by Oak Ridge National Laboratory have discovered the specific gene that controls an important symbiotic relationship between plants and soil fungi, and successfully facilitated the symbiosis in a plant that
OAK RIDGE, Tenn., May 7, 2019—The U.S. Department of Energy today announced a contract with Cray Inc. to build the Frontier supercomputer at Oak Ridge National Laboratory, which is anticipated to debut in 2021 as the world’s most powerful computer with a performance of greater than 1.5 exaflops.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.